Jazz Pharmaceuticals PLC (JAZZ) saw its stock price plummet 6.16% in Tuesday's trading session following the release of its first-quarter 2025 financial results, which significantly missed analyst expectations across key metrics.
The biopharmaceutical company reported Q1 revenue of $897.841 million, falling short of the IBES estimate of $985.4 million. Adjusted earnings per share (EPS) came in at $1.68, well below the expected $4.66. The company's adjusted net income for the quarter was $105.233 million, considerably lower than the estimated $288.6 million. Jazz Pharmaceuticals also reported a net loss of $92.541 million, translating to a loss per share of $1.52.
In light of these disappointing results, Jazz Pharmaceuticals announced updates to its 2025 financial guidance, though specific details were not immediately available. Investors and analysts will likely be closely monitoring the company's future outlook and potential strategies to improve performance in the coming quarters.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。